Literature DB >> 16945507

Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine.

Trawat Attarbaschi1, Julia Sacher, Thomas Geiss-Granadia, Nikolas Klein, Nilufar Mossaheb, Rupert Lanzenberger, Susanne Asenbaum, Robert Dudczak, Siegfried Kasper, Johannes Tauscher.   

Abstract

We explored the relationship between striatal dopamine-2 (D(2)) receptor occupancy and extra-pyramidal symptoms (EPS) in bipolar patients receiving olanzapine. Seventeen patients with a DSM-IV diagnosis of bipolar disorder were treated with 5-45 mg/day olanzapine for at least 14 days. After that period, D(2) receptor occupancy was determined using Iodobenzamide (IBZM) and SPECT. EPS were assessed by the Simpson-Angus Scale (SAS) and Barnes-Akathisia Scale (BAS). We found a dose-dependent increase in occupancy: 5 mg led to 28-50%, 10 mg to 40-68%, 15 mg to 69%, 20 mg to 57-66%, 30 mg to 66% and 45 mg to 80% D(2) receptor occupancy; and a significant correlation between plasma levels and occupancy (R(2)=.55, P=.001). Similar to schizophrenic patients, bipolar patients did not exhibit EPS at D(2) occupancy levels of 28 to 80%. Although we did not find an increased vulnerability for acute EPS in bipolar patients receiving olanzapine at clinical relevant doses, this needs to be replicated with larger sample sizes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945507     DOI: 10.1016/j.euroneuro.2006.07.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

1.  Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.

Authors:  Yewon Cheon; Jee-Young Park; Hiren R Modi; Hyung-Wook Kim; Ho-Joo Lee; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport
Journal:  J Neurochem       Date:  2011-09-20       Impact factor: 5.372

Review 2.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

3.  A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.

Authors:  Andy R Eugene; Jolanta Masiak
Journal:  Nord J Psychiatry       Date:  2017-05-09       Impact factor: 2.202

Review 4.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

5.  Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area.

Authors:  Anuradha Madhavan; Emanuela Argilli; Antonello Bonci; Jennifer L Whistler
Journal:  J Neurosci       Date:  2013-07-24       Impact factor: 6.167

Review 6.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Clinical pharmacology of atypical antipsychotics: an update.

Authors:  M C Mauri; S Paletta; M Maffini; A Colasanti; F Dragogna; C Di Pace; A C Altamura
Journal:  EXCLI J       Date:  2014-10-13       Impact factor: 4.068

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.